What is Oryzon Genomics S.A?
, a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 292.99M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.